Monocytes and neutrophils as ‘bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma – results from a randomised phase II trial by Donskov, F et al.
Monocytes and neutrophils as ‘bad guys’ for the outcome of
interleukin-2 with and without histamine in metastatic renal
cell carcinoma – results from a randomised phase II trial
F Donskov*,1,2, M Hokland
2, N Marcussen
3, HH Torp Madsen
4 and H von der Maase
1
1Department of Oncology, Aarhus University Hospital, Denmark;
2Department of Medical Microbiology and Immunology, University of Aarhus, Denmark;
3Department of Pathology, Aarhus University Hospital, Denmark;
4Department of Radiology, Aarhus University Hospital, Denmark
Histamine (HDC) inhibits formation and release of phagocyte-derived reactive oxygen species, and thereby protects natural killer
(NK) and T cells against oxidative damage. Thus, the addition of histamine may potentially improve the efficacy of interleukin-2 (IL-2).
We have explored this potential mechanism clinically in two randomised phase II trials in metastatic renal cell carcinoma (mRCC). In
parallel with the clinical trial in Denmark (n¼63), we obtained serial blood samples and tumour biopsies searching for a potential
histamine effect in situ. At baseline and on-treatment weeks 3 and 8, we monitored the ‘good guys’ (i.e. NK and T cells) and ‘bad guys’
(i.e. monocytes/macrophages and neutrophils) simultaneously in blood (n¼59) and tumour tissue (n¼44). Patients with high
number of monocytes and neutrophils in peripheral blood had very poor survival, with apparently no benefit from either IL-2 alone or
IL-2/HDC treatment. Blood monocytes (r¼ 0.36, P¼0.01) and neutrophils (r¼ 0.46, P¼0.001) were negatively correlated with
cytotoxicity, whereas blood NK cells were positively correlated with cytotoxicity (r¼0.39, P¼0.002). Treatment with IL-2 alone
resulted in a significantly higher number of circulating monocytes (P¼0.037) and intratumoral macrophages (P¼0.005) compared
with baseline. In contrast, IL-2/HDC resulted in an unchanged number of circulating monocytes and intratumoral macrophages, and in
addition, a significantly increased number of intratumoral CD56
þ NK cells (P¼0.008) and CD8
þ T cells (P¼0.019) compared with
baseline. The study provides evidence that circulating monocytes and neutrophils are powerful negative prognostic factors for IL-2-
based immunotherapy and establishes a biological rationale for the potential use of histamine in conjunction with IL-2 in mRCC.
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The observation that many cancers in adults arise in the setting of
chronic inflammation has opened up a research field that has been
crucial for our understanding and ultimately has established a new
paradigm (Vakkila and Lotze, 2004). Solid tumours are not just
composed of malignant cells (Hanahan and Weinberg, 2000), but
are complex tissues in which tumour cells have attracted and
educated tumour-infiltrating leucocytes (especially macrophages,
neutrophils and mast cells) to serve as active collaborators
(Coussens and Werb, 2001; Murdoch et al, 2004; Pollard, 2004).
Through the production of growth factors, proteases, angiogenic
mediators and reactive oxygen species (ROS), tumour-educated
macrophages promote tumour growth, angiogenesis, metastasis
and genomic instability (Balkwill and Mantovani, 2001; Coussens
and Werb, 2002; Lin and Pollard, 2004; Wyckoff et al, 2004; Chen
et al, 2005). Moreover, monocyte/macrophage-generated ROS are
highly toxic to antitumour lymphocytes such as natural killer (NK)
cells and T cells with the result that these cells undergo apoptosis
(Hansson et al, 1996; Kono et al, 1996; Malmberg, 2004).
Monocytes/macrophages and neutrophils therefore represent
an important drug-target for cancer treatment, with the aim of
reducing the number and/or function of these cells. Extensive
laboratory work for a decennium has identified histamine
dihydrochloride (HDC) as an anti-phagocyte drug-candidate
(Hellstrand, 2002). Targeting NADPH-oxidase through binding
to the H2-receptor on monocytes (Hellstrand and Hermodsson,
1986) and neutrophils (Betten et al, 2003), HDC specifically blocks
the formation and release of hydrogen peroxide (H2O2), thereby
protecting NK and T cells from oxygen radical-induced inhibition
and apoptosis (Hellstrand et al, 1994). Thus, NK and T cells remain
viable and responsive to interleukin-2 (IL-2) (Hellstrand et al,
1990; Hellstrand and Hermodsson, 1990; Asea et al, 1996). IL-2 has
no direct impact on tumour cells (Rosenberg, 2001) but requires
NK and T-cells for tumourlysis (Donskov et al, 2002a, 2004a,b).
Thus, the addition of histamine may potentially improve the
efficacy of IL-2.
We have explored this potential mechanism clinically in a
randomised phase II trial in metastatic renal cell carcinoma
(mRCC) (Donskov et al, 2005). As a supplement to the clinical trial
in Denmark, the present biological study was initiated to search for
a potential histamine effect in situ.
MATERIALS AND METHODS
Patients and treatment
Two randomised phase II trials of IL-2 with and without HDC were
run in parallel, one in Aarhus, Denmark and one in Manchester,
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sUnited Kingdom (Donskov et al, 2005). Only patients randomised
in the Danish study were included in the blood and tumour study.
The local ethics committee approved the study. All subjects gave
written informed consent before blood samples and tumour
biopsies. Study design, data accrual, data analyses and manuscript
preparation were performed entirely by the authors.
In order to be able to correlate the baseline and on-treatment
blood and tumour parameters with the biological effect of IL-2
with and without histamine, it was predefined that only patients
receiving at least 80% of the scheduled drug dose within the first
treatment course were assessable for the present analyses.
Patients were consecutively randomised to receive either IL-2/
HDC or IL-2 alone. One cycle consisted of IL-2 (Aldesleukin, rIL-2,
Proleukin
s, Chiron, The Netherlands) as a fixed dose, 18 MIU s.c.
once daily, 5 days per week for 3 weeks followed by 2 weeks rest.
Histamine dihydrochloride (HDC, Ceplenet, supplied by Maxim
Pharmaceuticals Inc., San Diego, USA), 1.0mg was added twice
daily, concomitantly with IL-2. Patients were evaluated for
objective response, according to standard WHO criteria (Miller
et al, 1981), every two cycles (10 weeks). A maximum of four
treatment cycles was given.
Tumour samples
Core needle biopsies (18G cutting needle) were collected by
standard ultrasound-guided procedures before treatment (base-
line) and at day 2 in weeks 3 and 8. The week 3 and week 8 time
points were selected to coincide with routine outpatient visit,
according to the immunotherapy schedule. A total of 98 biopsies
were obtained (Table 1) at baseline from 44 patients (IL-2/HDC,
n¼21; IL-2, n¼23), at week 3 from 29 patients (IL-2/HDC, n¼14;
IL-2, n¼15) and at week 8 from 25 patients (IL-2/HDC, n¼12;
IL-2, n¼13). Based on well-known prognostic factors of MSKCC
(Motzer et al, 1999), there were no significant differences between
the baseline patient group and the week 3 or the week 8 group,
P¼0.8 and P¼0.15, respectively, (Fisher’s exact test). There was
no significant difference between tumour histology types (IL-2/
HDC, clear cell RCC 82%; IL-2, clear cell RCC 88%) (P¼0.49).
Biopsies were performed from accessible tumour locations:
kidney, n¼42; liver, n¼17; lung/pleura/chest wall, n¼13;
abdominal/pelvic soft tissue, n¼10; lymph node, n¼9; subcutis,
n¼7; kidney bed, n¼6; and muscle, n¼2; some patients had
biopsies from more than one location. On-treatment biopsies were
obtained from the same tumour as the baseline biopsy.
Unfortunately, it showed up that none of the subsequent CR
patients had accessible baseline tumours for core needle biopsies.
Thus, these CR patients were not included in the statistical
analyses for the tumour variables but were, however, included in
the statistical analyses for the blood variables.
Immunohistochemistry
Immunohistochemistry used standard procedures, as described in
our previous studies (Donskov et al, 2002a, 2004a). Paraffin
sections were stained with monoclonal antibodies from Dako-
Cytomation, Denmark, CD8 (M7103 1:100), CD20 (M0755 1:500);
NovoCastra, Denmark, CD4 (NCL-CD4-1F6 1:50), CD56 (NCL-
CD56-1B6 1:40), MACRO (NCL-MACRO 1:80); Pharmingen,
Denmark, CD57 (33251A 1:500), CD66b (33731A 1:100) and
Ramcon, Denmark, zeta (IM2549 1:20). Primary antibodies were
detected using the Envision-peroxidase system (K4000, Dako-
Cytomation). All staining was performed in a TechMate automatic
immunohistochemistry staining machine, (DakoCytomation,
Denmark).
Immunohistochemical evaluation
Intratumoural immune cells were counted by an objective and
reproducible stereological method (Gundersen et al, 1988). A
computer-generated unbiased counting frame was used to perform
measurements. The first field of vision was chosen at random, after
which the computer systematically sampled the subsequent fields
of vision within the entire tumour biopsy. Necrosis, artefacts and
fibrous areas were omitted. Using a  40 objective, a total number
of 40 fields (4951mm
2 each) were counted, if the size of the tumour
biopsy allowed for it. Only cells showing specific surface staining, a
visible nucleus and location within the counting frame were
counted as positive. The mean number of cellsmm
 2 tumour
tissue was assessed for each patient. Staining was analysed blinded
by one observer. Selected sections were counted blinded by a
second experienced observer (NM) and a high level of reprodu-
cibility was demonstrated, as previously reported (Donskov
et al, 2004a).
Blood samples
Peripheral blood mononuclear cells were obtained (Table 1) and
isolated from lithium-heparinized whole blood samples by Ficoll–
Paque (Pharmacia Biotech, Uppsala, Sweden) gradient separation,
washed twice and cryopreserved at  1351C until use. Cytolytic
activity was determined by standard 4-h
51Cr-release assay against
K562 target, as previously reported in detail (Donskov et al,
2002a). Differential blood cell counts were determined by standard
Coulter counter technique (Coulter STKS) in the clinical chemistry
laboratory.
Cell surface phenotypes were determined by flow cytometry
using a Coulter XL-2 flow cytometer (Coulter Electronics, Florida).
Data were analysed using the Flow-Jo software (Treestar, San
Carlos, CA). Direct fluorochrome-conjugated antibodies (FITC or
PE) were purchased from DakoCytomation, Denmark (CD3, CD4,
CD8, CD20) and Becton Dickinson, Denmark (CD16, CD56, CD57,
CD69). Intracellular zeta expression was investigated on permea-
bilised cells, using 2H2D9 (TIA-2) PE-conjugated MoAb (Ramcon,
Denmark). Relevant isotype controls were purchased from
DakoCytomation.
Statistics
Overall survival time was measured from the first day of treatment
until death or last follow-up evaluation. The relationship between
assessed parameters and treatment arm was evaluated using the
nonparametric Mann–Whitney U-test. The significance of changes
from baseline to week 3 or to week 8 was assessed using the
Wilcoxon signed rank test for paired samples. Differences in
patient characteristics and response rates were analysed by Fisher’s
exact test. The cumulated survival rate was analysed by Kaplan–
Meier and the log-rank test was used to analyse for survival
differences among subgroups of patients. The median follow-up
period was 43 months (range 32–51 months). No patients were
Table 1 Number of tumour biopsies and blood samples
Week 0 3 8
Number of patients on-treatment
at the indicated time point
59 57 55
Number blood samples 59 (100%) 54 (95%) 52 (95%)
Number tumour biopsies 44 (75%) 29 (51%) 25 (45%)
Percentages indicate the number of samples obtained compared to the number of
patients on-treatment at the indicated time point. The main reasons for not having a
biopsy were withdrawal of consent and tumour necrosis. Not having a blood sample
was due to logistic reasons.
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slost to follow-up. Data were updated April 14, 2005. Statistical
analyses were performed using SPSS v11.0.
RESULTS
Overall clinical outcome
Between August 2000 and August 2002, 63 patients with mRCC
were enrolled in a Danish single-centre randomised phase II trial.
Thirty-three patients were randomly assigned to IL-2/HDC therapy
and 30 to IL-2 alone. The clinical outcome of this and a parallel UK
study has been published separately (Donskov et al, 2005). In
summary, our Danish study showed a statistically significant
1-year survival benefit (76 vs 47%, P¼0.03) and a trend towards
an improved median survival time (18.3 vs 11.4 months, P¼0.07)
and an improved clinical benefit (CRþPRþSD) (58 vs 37%,
P¼0.10) in favour of IL-2/HDC compared with IL-2 alone. Overall
response rate was not significantly different between the two
treatment groups.
The present analyses were based on 59 out of the 63 patients,
receiving at least 80% of the scheduled drug dose in the first
treatment course, in order to assess the biological effect of
IL-2 with and without histamine in relation to baseline and
on-treatment blood samples and tumour-tissue biopsies.
Patient characteristics were generally well balanced across
treatment arms, although slightly more patients on the IL-2 arm
had liver metastases and more patients on the IL-2/HDC arm were
males (Table 2). These differences were not statistically significant
(P¼0.18 and P¼0.054, respectively).
Clinical outcome stratified for blood monocytes,
neutrophils, NK and T cells
The prognostic impact of monocytes, neutrophils, NK and T-cells
was analysed. As IL-2 treatment may induce considerably changes
in the number and function of immune cells, baseline as well
as on-treatment week 3 and week 8 values were correlated with
treatment outcome. By keeping the on-treatment analyses de-
linked from baseline, we evaluated the potential prognostic impact
of high vs low numbers of immune cells, independently of previous
measurements – with special emphasis on a possible histamine
effect. Dichotomy of the variables was done at the median values.
For baseline neutrophils, the median value (5.46) was close to the
Table 2 Baseline patient characteristics
IL-2 plus Histamine
Study Group
N¼30
IL-2 alone
Control Group
N¼29
N % N %
Median age, years (range) 55 (31–69) 60 (36–69)
Male 24 80 16 55
Karnofsky performance status
100 16 53 12 41
90 10 33 13 45
8 0 27 27
7 0 27 27
Metastasis-free interval p1
year
22 73 20 69
Baseline blood neutrophils
Median ( 10
9l
 1), (range) 5.43 (2.61–15.91) 5.54 (2.01–10.33)
Baseline blood monocytes
Median ( 10
9l
 1), (range) 0.74 (0.35–1.51) 0.69 (0.32–1.11)
Baseline blood CD16
+56
+
NK-cells
Median ( 10
9l
 1), (range) 0.1 (0.02–0.36) 0.06 (0.01–0.39
Prior therapy
Nephrectomy 17 57 18 62
Excision of metastatic lesions 3 10 1 3
Number of disease organ sites
12 7 3 1 0
2 7 23 7 24
3 or more 21 70 19 66
Most common sites of disease
Primary kidney tumour 13 43 12 41
Local recurrence kidney bed 4 13 5 17
Lung/pleura 23 77 22 76
Lung metastasis alone 1 3 0 0
Lymph node 21 70 17 59
Liver 3 10 7 24
Bone 11 37 10 35
Soft tissue 5 17 4 14
MSKCC prognostic criteria
a
Favorable prognosis 6 20 5 17
Intermediate prognosis 20 63 18 62
Poor prognosis 4 13 6 21
aMemorial Sloan–Kettering Cancer Center (Motzer et al, 1999).
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Figure 1 Peripheral blood monocytes, neutrophils and NK cells
(CD16
þ56
þ) as prognostic factors for IL-2 based immunotherapy. High
levels of monocytes and neutrophils were correlated with short survival.
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spredefined cutoff level of 6.0 10
9l
 1 (Lopez et al, 1996), which
therefore was used as cutoff for the analyses. High levels of
monocytes at week 8 (P¼0.009) and neutrophils at baseline and
at week 8 (P¼0.014 and P¼0.0002, respectively) were correlated
with short survival (Figure 1). High levels of NK cells at baseline
were correlated with long survival, however, of borderline
significance (P¼0.08). Baseline monocytes and NK cells at week
8 were not significantly correlated with survival. Further
stratification by treatment assignment is shown in Figure 2.
Patients with high number of monocytes and neutrophils in
peripheral blood had a very poor survival, with apparently
no benefit from either IL-2 alone or IL-2/HDC treatment.
In contrast, survival was significantly improved in the IL-2/HDC
group compared with the IL-2 alone group in patients with
low number of baseline monocytes (P¼0.005), low number of
baseline neutrophils (P¼0.043), low number of neutrophils at
week 8 (P¼0.041) and high number of NK cells at week 8
(P¼0.025). The same trend, however, of only borderline
significance, was seen in patients with low monocytes at week 8
(P¼0.07) and low NK cells at week 0 (P¼0.07) (Figure 2).
Monocytes, neutrophils and NK cells, measured on week 3, showed
the same trend as obtained at baseline and week 8 (data not
shown).
We also evaluated blood lymphocyte subsets expressing CD4
þ,
CD8
þ, CD56
þ, CD56
dim, CD56
bright, CD3
 CD56
þ, CD56
þCD57
þ
and CD57
þ. In general, the survival curves for these lymphocyte
subsets were similar to the survival curves for the CD16
þ56
þNK-
cell. Thus, no significant survival differences were observed
between ‘high’ and ‘low’ lymphocyte subsets. However, long-term
survival was especially noted in patients treated with IL-2/HDC
(data not shown).
Circulating blood phagocytes
The potential histamine effect on circulating phagocytes in
peripheral blood was assessed in situ in blood samples obtained
at baseline and during therapy at weeks 3 and 8. Non-PD patients
(CRþPRþSD) treated with IL-2/HDC had unchanged number of
circulating monocytes during treatment compared with baseline.
In contrast, non-PD patients treated with IL-2 alone had
significantly increased numbers at weeks 3 (P¼0.037) and 8
(P¼0.043) compared with baseline (Figure 3). Moreover, all PD
patients had significantly increased monocyte numbers at weeks 3
and 8 compared with baseline, both for patients treated with IL-2/
HDC (P¼0.01 and P¼0.008, respectively) and for patients treated
with IL-2 alone (P¼0.01 and P¼0.05, respectively), data not
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Figure 2 Peripheral blood neutrophils, monocytes and NK cells as prognostic factors stratified for treatment assignment. Kaplan–Meier plots at baseline
and week 8 in patients with metastatic renal cell carcinoma treated with interleukin-2 and HDC (—) or IL-2 alone (----) concerning survival for (A)
monocytes (B) neutrophils and (C) NK cells (CD16
þ56
þ). IL-2/HDC treatment resulted in long-term survival in patients with low numbers of monocytes
and neutrophils and patients with high number of NK cells in the peripheral blood. Vertical and horizontal axes, the survival probability and months of follow-
up, respectively. Tick marks (|) indicate last date of follow-up. The hazard ratio (HR) refers to IL-2/HDC relative to IL-2 alone. CI, confidence interval.
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sshown. Circulating neutrophils were evaluated similarly; however,
no statistically significant differences were found.
Tumour-infiltrating immune cells
The potential histamine effect on the leucocyte subsets infiltrating
the tumour tissue was assessed in situ in tumour core-needle
biopsies obtained at baseline and during treatment at weeks 3 and
8. A total of 98 tumour biopsies were analysed (IL-2/HDC, n¼47
and IL-2, n¼51) (Figure 4). Patients treated with IL-2/HDC had
significantly higher number of intratumoural CD56
þ NK cells at
weeks 3 (P¼0.008) and 8 (P¼0.016) and also higher number of
intratumoural CD8
þ T cells at week 8 (P¼0.019) compared with
baseline. In contrast, intratumoural macrophage numbers
remained unchanged at weeks 3 and 8 compared with baseline
(Figure 4). In comparison, patients treated with IL-2 alone had no
increased intratumoural NK or T cells, but did show a significantly
increased number of intratumoural macrophages at week 8
compared with baseline (P¼0.005).
Intratumoural neutrophils showed no significant differences
between treatment groups (data not shown)
Functional assays
An activation receptor for NK cells is CD16 (Herberman, 2002).
Therefore, we assessed CD16
þCD56
þNK cells in peripheral blood
as a functional assay. The number of CD16
þ56
þNK cells
increased median 350% (week 3) and 398% (week 8) compared
with baseline values (Po0.001 and Po0.001, respectively),
however, with no significant difference between the IL-2/HDC
and the IL-2 alone group. In parallel, in vitro cytotoxicity increased
median 121% (week 3) and 155% (week 8) compared with baseline
values. There was a significantly positive correlation between
blood CD16
þ56
þ NK cells and cytotoxicity at baseline (Spear-
man’s r¼0.39, P¼0.002), week 3 (r¼0.31, P¼0.02) and week 8
(r¼0.29, P¼0.03) (Figure 5). In contrast, there was a significantly
negative correlation between blood neutrophils and cytotoxicity
at week 3 (r¼ 0.29, P¼0.03) and week 8 (r¼ 0.46, P¼0.001)
and also between blood monocytes and cytotoxicity at week 8
(r¼ 0.36, P¼0.01) (Figure 5). The expression of the blood
lymphocyte activation marker CD69 was significantly higher at
week 8 compared with baseline in patients treated with IL-2/HDC
(P¼0.001), whereas no increase was observed in patients treated
with IL-2 alone. CD3-zeta chain expression in blood and tumour
did not show a statistically significant histamine effect compared
with the effect of IL-2 alone.
DISCUSSION
The results of the present biological part of our prospective
randomised phase II trial provide evidence for circulating
monocytes and neutrophils as negative prognostic factors for
IL-2-based immunotherapy. Clearly, patients with high numbers of
monocytes and neutrophils in peripheral blood had very poor
survival, with apparently no impact of either IL-2-alone or IL-2
plus histamine treatment. Blood monocytes and neutrophils were
negatively correlated with cytotoxicity, whereas blood NK cells
were positively correlated with cytotoxicity, although not all
differences achieved statistical significance, which may be due to
the relatively small patient number. Thus, our data are highly
supportive of the oxidative stress hypothesis formulated by
Hellstrand et al (2002). Previously, three large studies of
prognostic factors for IL-2 based immunotherapy in mRCC,
including a total of 1422 patients, have all identified baseline-
elevated neutrophils and biological signs of inflammation as poor
prognostic factors (Lopez et al, 1996; Negrier et al, 2002;
Atzpodien et al, 2003). Moreover, a reduction in blood monocytes
during IL-2 treatment has been correlated with clinical response
(Hermann et al, 1991). However, these studies were all purely
descriptive with no ability to explain their findings. It is particu-
larly noteworthy that the present study not only identifies baseline
and on-treatment-elevated neutrophils and monocytes as poor
prognostic factors, as we also did in a previous study (Donskov
et al, 2004a), but offers an explanation of these findings by
supporting the oxidative stress hypothesis. Our results therefore
add to the understanding of how reactive oxygen-radicals
influence the biological in vivo activity of immune cells during
IL-2 based immunotherapy.
Chronic immune activation and chronic inflammation have long
been suspected to be promoters of malignancy (Balkwill and
Mantovani, 2001; Coussens and Werb, 2002). Among macrophage
and neutrophils products, ROS may not only induce genomic
instability (O’Byrne and Dalgleish, 2001), but also damage
antitumour immune effector cells (Seaman et al, 1982; Hellstrand
et al, 1994; Hansson et al, 1996). Intratumoural macrophages
isolated from melanoma metastases inhibit NK-cell function by the
release of ROS (Kono et al, 1996). Intratumoural NK and T cells
isolated from mRCC show signs of oxidative damage (Finke et al,
1993; Tartour et al, 1995). IL-2 cannot activate NK cells in vitro
in the presence of monocytes or macrophages (Hellstrand and
Hermodsson, 1990). Based on these observations, it seems
convincing that the observed survival differences for patients in
the present study are caused by a phagocyte characteristic, namely
the production of ROS, although we did not perform any direct
measurements of ROS as purification methods and laboratory
processes are difficult to perform without inducing stimulation in
monocytes or neutrophils. Further investigation of the relation
between phagocytes, NK cells, T cells and ROS in blood and
tumour tissue is warranted, including direct measurements of
apoptosis and ROS levels.
Our data support a novel treatment strategy involving the
blocking of phagocyte-generated ROS by histamine, thereby
3.0
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1.5
1.0
0.5
0.0
Week 0  Week 3 Week 8
P=0.037 P=0.043
CR+ PR+SD CR+ PR+SD CR+ PR+SD
IL-2 + histamine
IL-2
Figure 3 Potential histamine effect on circulating monocytes during IL-2-
based treatment, assessed in situ. Treatment with IL-2/HDC (white boxes)
resulted in unchanged number of circulating monocytes in patients with
complete response (CR), partial responses (PR) and stable disease (SD)
compared with baseline values, whereas treatment with IL-2-alone (black
boxes) did not prevent a significant increased number compared with
baseline. All patient with progressive disease (PD) had significantly
increased monocyte numbers at weeks 3 and 8 compared with baseline,
irrespective of the treatment group. Vertical and horizontal axes,
10
9cellsl
 1 and response to immunotherapy, respectively. The box plots
represent the median (solid black line), the 25th and the 75th percentiles
(boxed) and the 10th and the 90th percentiles (error bars). ‘O’ indicate
outliers. ‘*’ indicate extremes.
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sprotecting NK and T cells from apoptosis and, thus, synergising
with IL-2 in inducing NK- and T-cell activation (Hellstrand and
Hermodsson, 1990; Hellstrand et al, 1990; Asea et al, 1996;
Hansson et al, 1999). Clearly, with regard to the ‘good guys’,
treatment with IL-2/HDC resulted in significantly higher numbers
of intratumoural NK and CD8
þT cells during treatment compared
with baseline. In contrast, treatment with IL-2 alone did not result
in an increased number of intratumoural NK or T cells. Moreover,
with regard to the ‘bad guys’, treatment with IL-2/HDC resulted in
an unchanged number of circulating monocytes and intratumoural
macrophages during treatment compared with baseline, whereas
treatment with IL-2-alone did not prevent a significantly higher
number of both circulating monocytes and intratumoural
macrophages developing during treatment compared with baseline.
It should be noted that low numbers of monocytes and neutrophils
or high number of NK cells in peripheral blood were correlated with
long-term survival. In these subgroups, a substantially increased
survival rate was observed in patients treated with IL-2/HDC
compared with patients treated with IL-2 alone. Thus, targeting
H2O2 by histamine seems to enhance the antitumour activity of IL-2
in situ in a subgroup of patients. Recently, a superoxide dismutase
mimetic, M40403, targeting superoxide (O2
K ) was reported to
enhance the antitumour action of IL-2 in mice models (Samlowski
et al, 2003). As a result, developing and assessing drugs that block
the generation of oxygen radicals as an adjunct to IL-2 is a viable
therapeutic opportunity in renal cell cancer.
A randomised phase II trial of IL-2 with and without HDC in
mRCC was run independently in Manchester, UK in parallel with
the present trial (Donskov et al, 2005). The two studies had exactly
the same clinical design and patient selection criteria. The outcome
of the individual studies differed as the Danish study (n¼63)
showed a trend towards improved efficacy in favour of IL-2/HDC,
whereas the UK study (n¼41) was negative for all end points
(Donskov et al, 2005). So, based on the randomised trials by
themselves, no clear-cut effect of adding histamine to IL-2 was
recognized. However, by the present biological analyses, a
potential effect of histamine was clearly demonstrated, empha-
sising the value of accompanying clinical trials with blood and
tumour tissue assessments. Indeed, the present assessment of the
oxidative stress hypothesis in blood and tumour tissue is the first
to establish a biological rationale – in humans – for the use of
histamine in conjunction with IL-2 despite several clinical trials
(Brune and Hellstrand, 1996; Mellqvist et al, 1999; Agarwala et al,
2002, 2004; Lurie et al, 2002; Schmidt et al, 2002; Donskov et al,
2002b). Previously, we have tested histamine in mRCC with
low-dose IL-2 and interferon-alpha (IFN) (Donskov et al, 2002b)
with no difference in treatment groups observed (Donskov et al,
2004a). However, the question of whether histamine might
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simprove efficacy with higher doses of IL-2 formed the basis for the
present randomised phase II study. Thus, in the present study, we
have doubled the dose of IL-2 compared to that in our first
IL-2/IFN/Histamine-study and the applied IL-2 dose can be
considered to be an intermediate dose level.
Since its introduction to the clinic in 1985 (Rosenberg et al,
1985), IL-2 remains the only established immunotherapy approved
by the US Food and Drug Administration for the treatment of
metastatic melanoma and mRCC. However, despite 20 years of
clinical trials, no combination therapy has proved better than IL-2
treatment alone in terms of long-term survival (Negrier et al, 1998;
McDermott et al, 2005). Thus, cancer immunotherapy is most
dependent on the application of advances in knowledge of basic
science and its translation to the clinic. The present study indicates
a direction for future clinical immunotherapy efforts.
In conclusion, our study provides evidence for circulating
monocytes and neutrophils as powerful negative prognostic factors
for IL-2-based immunotherapy and establishes a biological
rationale for the potential use of histamine in conjunction with
IL-2 in mRCC. However, patient numbers are too small to make
definitive conclusions. Thus, a large confirmatory randomised
phase III trial of IL-2 with and without histamine in mRCC
appropriately stratified for monocytes and neutrophils in blood
and tumour tissue is warranted.
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